- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05222438
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Phase II Trial Evaluating Safety and Efficacy of Loncastuximab Tesirine as a Maintenance Therapy Following Autologous Stem Cell Transplantation in High Risk Diffuse Large B-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent form (ICF)
- Age >18 years
Patients with relapsed refractory DLBCL with any of the following high-risk features for progression following autoSCT will be enrolled:
- Primary refractory lymphoma (failure to achieve complete remission as determined by the treating physician) following 1st line anthracycline containing chemotherapy
- Early relapsed lymphoma with an initial remission duration of less than 12 months following 1st line anthracycline containing chemotherapy
- Failure to achieve complete remission following salvage chemotherapy and positive PET-CT as defined by Lugano criteria (Deauville score of 4 or 5) prior to autoSCT
- Double hit lymphoma (DHL) or triple hit lymphoma (THL) confirmed by FISH testing by local pathology (defined as high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements)
- Double expressor lymphoma (DEL) as confirmed by immunohistochemistry (IHC) by local pathology (MYC and BCL2 or BCL6 positivity)
- CMYC rearranged (by FISH) DLBCL
- High IPI score (≥3 points)
- Stage 3-4 disease at diagnosis
- Extra-lymphatic disease
- High grade B cell lymphoma
- Eligible to undergo autologous stem cell transplantation as per local investigator assessment
- Availability of biopsy specimens confirming DLBCL relapse. Archival formalin-fixed paraffin-embedded (FFPE) tissue blocks or 15 unstained slides serial sections (5-10 μm in thickness) must be available prior to study enrollment. The pathology report must be available. IHC testing of CMYC, BCL2, and BCL6 expression, and FISH testing of CMYC, BCL2 and BCL6 gene rearrangement must be available prior to enrollment. CD19 expression status must be available prior to enrollment.
- Patients previously treated with CD19-targeted therapy (including CAR T) must have a subsequent biopsy and/or flow cytometry confirming CD19 positivity.
- ECOG Performance Status of 0, 1, or 2
- Life expectancy of at least 6 months
- Ability and willingness to comply with the study protocol procedures
- Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 9 months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least 6 months after the patient receives his last dose of loncastuximab tesirine
Exclusion Criteria:
- Contraindications to any of the individual components of autoSCT or loncastuximab tesirine.
- Prior exposure to loncastuximab tesirine
- Clinically significant effusion i.e. ascites, pleural or pericardial effusion requiring drainage or associated with shortness of breath
- Patients with ongoing toxicities of grade >1 from previous treatments except alopecia
- Patients with clinically significant history of liver disease including cirrhosis or hepatitis (viral hepatitis). However, treated viral hepatitis may be allowed Patients with history of severe skin disorders including Steven-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- Patients who are receiving any other investigational agents
- Grade 3b follicular lymphoma
- Burkitt's lymphoma
- Patients with known brain, spinal, or CSF involvement
- Systemic steroids (prednisone >20 mg/day or equivalent) and/or immunosuppressive medications
Unstable cardiovascular function that could affect compliance with the protocol:
- Symptomatic ischemia, or
- Congestive heart failure (CHF) of NYHA Class ≥3, or
- Myocardial infarction (MI) within 3 months
- Left ventricular ejection fraction <45% based on echocardiogram or MUGA scan obtained within 6 months prior to enrollment
- History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block.
Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg]):
-Patients with occult or prior HBV infection (defined as negative HBsAg and positive hepatitis B core antibody [HBcAb]) may be included if HBV DNA PCR is undetectable, provided that they are willing to undergo DNA testing on Day 1 of every cycle of study treatment. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination or prior but cured hepatitis B are eligible.
- Known history of HIV seropositive status
- Patients with a history of progressive multifocal leukoencephalopathy
Any of the following, unless abnormal laboratory values are due to underlying lymphoma per the investigator:
- Creatinine > 1.5 x ULN or a measured creatinine clearance < 40 mL/min
- AST or ALT > 2.5 x ULN
- Total bilirubin > 1.5 x ULN. Patients with documented Gilbert disease may be enrolled if total bilirubin is < 3 x ULN
- INR or PT > 1.5 x ULN in the absence of therapeutic anticoagulation
- PTT or aPTT > 1.5 x ULN in the absence of a lupus anticoagulant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Loncastuximab tesirine
Patients will start loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
Patients will receive IV infusion of loncastuximab tesirine 150 μg/kg at Q3W for the first 2 cycles followed by 75 μg/kg at Q3W for the remaining 6 cycles.
|
loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Outcome Measure
Time Frame: From the start date of treatment initation until the date of progression or death from any cause, whichever occurs first, assessed up to 1-year following autoSCT
|
Progression-free survival (PFS) assessments will be determined according to Lugano Response Criteria.
The distributions of time to event data will be graphically summarized using Kaplan-Meier (KM) curves and their median and confidence intervals will be estimated using KM estimates.
|
From the start date of treatment initation until the date of progression or death from any cause, whichever occurs first, assessed up to 1-year following autoSCT
|
Safety Outcome Measure
Time Frame: Up to 30 days after last dose of study treatment
|
Evaluate the safety and tolerability as defined by CTCAE 5.0 criteria
|
Up to 30 days after last dose of study treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dipenkumar Modi, M.D., Barbara Ann Karmanos Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Loncastuximab tesirine
Other Study ID Numbers
- 2021-047
- ADCT-402-001 (Other Identifier: ADC Therapeutics)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Diffuse Large B-cell Lymphoma
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Nordic NanovectorCompletedRefractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell LymphomaSpain, United Kingdom, Italy, United States, Germany
-
Incyte CorporationCompletedRefractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
Clinical Trials on loncastuximab tesirine
-
University of MiamiADC Therapeutics S.A.RecruitingMarginal Zone LymphomaUnited States
-
ADC Therapeutics S.A.No longer availableRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
-
M.D. Anderson Cancer CenterRecruitingLymphoma | Large B-cell LymphomaUnited States
-
ADC Therapeutics S.A.RecruitingDiffuse Large B-Cell Lymphoma | High-grade B-cell LymphomaTaiwan, Korea, Republic of, United States, Brazil
-
Mayur NarkhedeADC Therapeutics S.A.RecruitingChronic Lymphocytic LeukemiaUnited States
-
ADC Therapeutics S.A.CompletedDiffuse Large B-cell LymphomaSpain, United States, Italy, Puerto Rico
-
ADC Therapeutics S.A.TerminatedDiffuse Large B-Cell Lymphoma | Mantle Cell LymphomaUnited States, Spain, United Kingdom, France, Italy, Belgium
-
University of WashingtonRecruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Refractory Mantle Cell Lymphoma | Recurrent Follicular... and other conditionsUnited States
-
ADC Therapeutics S.A.RecruitingB-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin LymphomaUnited States, Spain, Italy, United Kingdom, Belgium, Czechia
-
ADC Therapeutics S.A.TerminatedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell LymphomaSpain, United States